AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 307.3 USD | +2.33% |
|
+12.18% | +6.70% |
| May. 08 | Mizuho Securities Raises Amgen's Price Target to $235 From $223 | MT |
| May. 06 | North American Morning Briefing : Stock Futures -2- | DJ |
Presenter SpeechTerence Flynn (Analysts)Great. Good morning, everybody. Thanks for joining us....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
300.3
USD
Average target price
313.3
USD
Spread / Average Target
+4.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.70% | 161B | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| -1.81% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Transcript : Amgen Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 08